News

Can Transparency Lower Prices and Improve Access to Pharmaceuticals? Five Questions We Think Matter a Lot

Friday, 29 March 2019

Transparency as a principle of good governance is not the same as transparency for improving access by lowering prices. In fact, the former often carries an opportunity cost on the latter. Developing country markets are, however, dominated by generic products and encouraging competition through sharing prices makes sense if capacities are there to use the data to inform procurement decisions and protect against collusion.

Read more »

OHE Lunchtime Seminar: Cascades of Care in Health Policy Analysis and Planning

Tuesday, 26 March 2019

‘Cascades of care’ have emerged as an attractive tool for assessing access to care for numerous chronic diseases. Dr Haacker will examine the use of cascades of care across diseases and populations, evaluate the use of cross-sectional targets in disease control strategies (e.g., the UNAIDS 90-90-90 targets), and address implications for cost-effectiveness analysis.

Read more »

Is Rate Of Return Pricing A Useful Approach When Value-Based Pricing Is Not Appropriate?

Friday, 22 March 2019

Value-based pricing (VBP) is an efficient method for pricing new drugs. Rate of return pricing could, however, be useful in two cases: treatments for ultra-rare diseases, and ‘cures’ for conditions currently being treated at great expense. Rate of return pricing gives rise to challenges. Two are (i) finding proxy estimates of development costs including failures, and (ii) driving future research towards discovering high-value treatments.

Read more »

Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England

Wednesday, 20 March 2019

Estimating a cost-effectiveness threshold reflecting the opportunity cost of adopting a new technology in a health system is not easy. A new OHE report provides empirical evidence on the relationship between health outcomes and health expenditures in England. Results suggest that setting a cost-effectiveness criterion for NICE may not be capable of being synthesised using scientific methods alone, but involve political judgements.

Read more »

Pages